Business Description
ISIN : US05464T1043
Total Employee Number:
925Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.42 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 2.7 | |||||
Debt-to-EBITDA | -1.28 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.54 | |||||
Beneish M-Score | -2.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 118.5 | |||||
3-Year EBITDA Growth Rate | 7.8 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | 13.2 | |||||
3-Year Book Growth Rate | -11.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 53.78 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.28 | |||||
9-Day RSI | 48.01 | |||||
14-Day RSI | 44.68 | |||||
3-1 Month Momentum % | -9.53 | |||||
6-1 Month Momentum % | 31.05 | |||||
12-1 Month Momentum % | 64.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 1.34 | |||||
Cash Ratio | 0.69 | |||||
Days Inventory | 193.93 | |||||
Days Sales Outstanding | 107.95 | |||||
Days Payable | 551.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | -0.49 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.24 | |||||
Operating Margin % | -23.55 | |||||
Net Margin % | -24.68 | |||||
EBITDA Margin % | -22.68 | |||||
FCF Margin % | -9.27 | |||||
OCF Margin % | -9.18 | |||||
ROE % | -256.9 | |||||
ROA % | -27.58 | |||||
ROIC % | -84.59 | |||||
3-Year ROIIC % | 6.61 | |||||
ROC (Joel Greenblatt) % | -866 | |||||
ROCE % | -62.31 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 39.16 | |||||
PS Ratio | 13.81 | |||||
PB Ratio | 132.15 | |||||
Price-to-Tangible-Book | 323.26 | |||||
EV-to-EBIT | -58.64 | |||||
EV-to-Forward-EBIT | 130.76 | |||||
EV-to-EBITDA | -61.95 | |||||
EV-to-Forward-EBITDA | 117.4 | |||||
EV-to-Revenue | 14.05 | |||||
EV-to-Forward-Revenue | 6.54 | |||||
EV-to-FCF | -151.63 | |||||
Earnings Yield (Greenblatt) % | -1.71 | |||||
FCF Yield % | -0.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AXSM
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Axsome Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 776.569 | ||
| EPS (TTM) ($) | -3.75 | ||
| Beta | 1.2154 | ||
| 3-Year Sharpe Ratio | 0.85 | ||
| 3-Year Sortino Ratio | 1.66 | ||
| Volatility % | 40 | ||
| 14-Day RSI | 44.68 | ||
| 14-Day ATR ($) | 7.090786 | ||
| 20-Day SMA ($) | 209.066 | ||
| 12-1 Month Momentum % | 64.54 | ||
| 52-Week Range ($) | 112.9 - 260.19 | ||
| Shares Outstanding (Mil) | 52.38 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Axsome Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Axsome Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-23 08:00 | In 168 days | ||
| Annual report for 2026 | 2027-02-23 | In 167 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-23 | In 167 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-03 08:00 | In 56 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 55 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-16 10:00 | In 8 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 13:50 | In 6 days | ||
| Guidance call for 2026 | 2026-09-10 14:45 | In 2 days | ||
| Wells Fargo 21st Annual Healthcare Conference Fireside Chat | 2026-09-09 15:45 | In 1 day | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 08:00 | 212.74 (+1.24%) |
Axsome Therapeutics Inc Frequently Asked Questions
Guru Commentaries on NAS:AXSM
We added exposure to therapeutics with the addition of three commercial stage companies with promising growth potential. Importantly, two of these companies are already profitable, with the third potentially profitable early next year. Axsome Therapeutics has multiple marketed products, although the most exciting growth opportunity is its recently approved therapy Auvelity, which is a novel treatment for agitation due to dementia/Alzheimer’s disease.
Axsome Therapeutics is a high-growth, commercial-stage biotechnology company focused on central nervous systems disorders. We believe that its key drug, Auvelity, has a large commercial opportunity with approval in Major Depressive Disorder and recent expansion into Alzheimer’s Disease Agitation.
Axsome Therapeutics Inc. (AXSM) was a new addition to investor portfolios in January of 2025 and has been a positive contributor since. Axsome is a biopharmaceutical company focused on central nervous system conditions such as Alzheimer’s Disease Agitation, Major Depressive Disorder, Migraines, and Fibromyalgia. Their products target a broad range of serious conditions that impact over 150 million people in the United States. Axsome has 4 products commercially available today with 2 others in late stages of approval. These products have the potential to provide over $16 billion in peak sales in comparison to Axsome’s $630 million of revenue in 2025. Auvelity, an oral drug for major depressive disorder, has quickly ramped to over $500 million in sales in 2025. The FDA has given Axsome accelerated review for a label expansion to Alzheimer’s Disease Agitation, which could be a significant catalyst for the stock.
Press Release
Articles on Axsome Therapeutics Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
